Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (PCRX) announced inducement grants to 15 new employees on February 4, 2025, under its Amended and Restated 2014 Inducement Plan. The grants include significant awards to two key executive appointments: Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer.
Teehan received options to purchase 99,500 shares at $26.59 per share and 54,000 restricted stock units (RSUs). Corbett received options for 88,400 shares at $26.59 and 46,000 RSUs. Additionally, four employees received options to purchase 20,600 shares, and 13 employees received 45,400 RSUs.
The stock options have a 10-year term with four-year vesting schedules. RSUs vest in four equal annual installments starting February 1, 2026. All awards are subject to continued employment with Pacira.
Pacira BioSciences (PCRX) announced significant changes to its Board of Directors. Laura Brege has been appointed as Chair of the Board, while former Chair Paul J. Hastings and Andreas Wicki have retired. The Board now consists of nine directors, with eight being independent and five joining since October 2023.
Brege brings over a decade of experience with Pacira and 30 years of executive management expertise in the pharmaceutical and biotechnology industries. She has held executive positions at BridgeBio Pharma, Onyx Pharmaceuticals, and COR Therapeutics.
These changes are part of Pacira's ongoing Board transformation, which began 15 months ago with the appointment of four new independent directors. Additionally, Alethia Young has been appointed as the new Chair of the Audit Committee, succeeding Brege in this role.
Pacira BioSciences (NASDAQ: PCRX) has announced two key appointments to its executive leadership team as part of its '5x30' strategy to become an innovative biopharmaceutical organization. Brendan Teehan has been appointed as Chief Commercial Officer, bringing 30 years of experience in building commercial teams across multiple therapeutic categories. Previously, he served as Chief Operating Officer at Acadia Pharmaceuticals.
Krys Corbett joins as Chief Business Officer, contributing over 25 years of experience in business development and strategic transactions. She previously led portfolio and product strategy at Lyell Immunopharma and served as Head of Business Development at Oric Pharmaceuticals.
These appointments are intended to enhance the company's execution of its growth strategy, combining Teehan's expertise in maximizing pharmaceutical brands with Corbett's portfolio management and partnering experience.
Pacira BioSciences (PCRX) announced its five-year strategic plan '5x30' alongside preliminary unaudited 2024 revenue of $701.0 million, up from $675.0 million in 2023. The 5x30 plan aims to achieve five key objectives by 2030, including treating over three million patients annually, achieving double-digit revenue growth, improving gross margin by five percentage points, expanding clinical pipeline with five novel programs, and establishing five partnerships.
Key 2024 revenue highlights include EXPAREL net product sales of $549.0 million (up from $538.1 million in 2023), ZILRETTA sales of $118.1 million (up from $111.1 million), and iovera° sales of $22.8 million (up from $19.7 million). Fourth quarter EXPAREL sales reached $147.7 million, with growth driven by volume increases and pricing, partially offset by vial mix shifts and GPO partnership discounts.
Pacira BioSciences (Nasdaq: PCRX) has received FDA 510(k) clearance for a new Smart Tip designed for the iovera° system to manage chronic low back pain via long-lasting medial branch nerve block. The iovera° system uses cryoneurolysis, applying focused cold therapy to nerves to interrupt pain signals temporarily. The new 25-gauge, 180-mm Smart Tip treats deeper nerves, including the medial branch nerve, and is designed to relieve chronic low back pain associated with facet-mediated pain.
Chronic low back pain is a significant health issue in the U.S., leading to disability and opioid prescriptions. The iovera° system provides an alternative to radiofrequency ablation (RFA), which has limitations like delayed pain relief and potential tissue damage. A single-center randomized pilot study showed that patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days compared to RFA-treated patients. Additionally, iovera° patients exhibited significant functional improvements and greater satisfaction with pain management.
The FDA clearance of this new Smart Tip is a step forward in offering drug-free, effective pain relief for millions of Americans with chronic back pain.
Pacira BioSciences (NASDAQ: PCRX) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 AM PT (1:30 PM EST).
Interested parties can access the live audio presentation through the 'Events' page on the company's investor website at investor.pacira.com. The company will make a replay of the webcast available for a two-week period following the event.
VectorY Therapeutics announces Jim Scibetta as new CEO, while former CEO Sander van Deventer transitions to President of R&D. The company's lead program, VTx-002, a vectorized antibody targeting TDP-43 for ALS treatment, advances to IND-enabling studies following positive FDA feedback. The company recently completed a $138 million Series A funding round co-led by EQT Life Sciences and Forbion, and expanded its presence with a new office in Boston.
Scibetta brings over 20 years of executive leadership experience, including roles as CEO of Maverick Therapeutics and President of Pacira BioSciences. VTx-002 aims to delay ALS disease progression by targeting TDP-43 pathology and is expected to enter clinical trials by the end of 2025.
DOMA Perpetual Capital Management, owning 4.14% of Pacira BioSciences (NASDAQ: PCRX), announced plans to nominate four independent director candidates for Pacira's 2025 annual stockholder meeting. DOMA has hired Olshan Frome Wolosky LLP as legal counsel for company dealings.
Expressing strong confidence in Pacira's intellectual property value, DOMA believes the company's stock is significantly undervalued. They are urging Pacira to initiate an immediate stock tender offer for 10 million shares using available cash reserves, followed by executing their previously approved $150 million buyback program using the company's healthy and growing free cash flow.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to four new employees on December 3, 2024. The awards include:
- Stock options to purchase 19,800 shares of common stock at $16.68 per share, with a 10-year term and four-year vesting schedule
- 23,600 restricted stock units (RSUs) vesting annually in four equal installments starting December 1, 2024
The awards were approved by the Compensation Committee under Pacira's Amended and Restated 2014 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). Vesting is contingent upon continued employment.
Pacira BioSciences (Nasdaq: PCRX) has been awarded U.S. Patent No. 12,156,940 for EXPAREL's chemical composition, providing protection until July 2044. This patent is the first in a new family related to EXPAREL produced by their enhanced manufacturing process in San Diego, approved by FDA in February 2024. The company plans to list the patent in the FDA Orange Book and file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA. Additionally, two new patents (No. 12,151,024 and 12,144,890) were issued, extending protection until January 2041.